Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
ln Vitro |
In the absence of IBMX, sinesetin (40 μM, 2 d) modifies adipogenic factors, promoting adipogenesis in 3T3-L1 preadipocytes [1]. On Jurkat and CCRF-CEM cells, sinesetin (12-200 μM, 24-48 h) shows notable cytotoxic effects in a dose- and time-dependent manner [4]. Jurkat cells undergo sub-G1 phase induction and cell transplantation when exposed to 100 μM sinensetin for 48 hours [4]. Assay [1]
|
---|---|
ln Vivo |
Sinensetin (50 mg/kg, single dose, intraperitoneal injection) exerts anti-inflammatory properties in a carrageenan-induced mouse paw activation model [5].
|
Cell Assay |
Western Blot Analysis[1]
Cell Types: 3T3-L1 Tested Concentrations: 2, 10, 40 μM Incubation Duration: 24 days Experimental Results: Cellular lipid accumulation and triglyceride content increased in a dose-dependent manner. The expression of PPARγ1, PPARγ2, C/EBPα, and aP2 was increased. Cell proliferation assay [4] Cell Types: CCRF-CEM cells, Jurkat Tested Concentrations: 6.25–100 μM Incubation Duration: 24 or 48 hrs (hours) Experimental Results: Different concentrations of artemisia inhibited cell viability for 24 hrs (hours) and 48 hrs (hours). Apoptosis analysis [4] Cell Types: Jurkat Cell Tested Concentrations: 50 μM, 100 μM Incubation Duration: 24 hrs (hours) and 48 hrs (hours) Experimental Results: Induction of sub-G1 population and apoptosis. |
Animal Protocol |
Animal/Disease Models: Carrageenan-induced paw edema in male C57BL/6 mice [5] 50 mg/kg, single
Doses: intraperitoneal (ip) injection Experimental Results: Carrageenan-treated paw volume at 6 hrs (hrs (hours)) Increase slows down. |
References |
[1]. Kang SI et al. Sinensetin enhances adipogenesis and lipolysis by increasing cyclic adenosine monophosphate levels in 3T3-L1 adipocytes. Biol Pharm Bull. 2015;38(4):552-8.
[2]. Shin HS et al. Sinensetin attenuates LPS-induced inflammation by regulating the protein level of IκB-α. Biosci Biotechnol Biochem. 2012;76(4):847-9. [3]. Lam IK et al. In vitro and in vivo structure and activity relationship analysis of polymethoxylated flavonoids: identifying sinensetin as a novel antiangiogenesis agent. Mol Nutr Food Res. 2012 Jun;56(6):945-56. [4]. Kok-Tong Tan, et al. Sinensetin induces apoptosis and autophagy in the treatment of human T-cell lymphoma. Anticancer Drugs. 2019, 30, 5. [5]. Mirka Laavola, et al. Flavonoids eupatorin and sinensetin present in Orthosiphon stamineus leaves inhibit inflammatory gene expression and STAT1 activation. Planta Med. 2012, 78, 8. |
Molecular Formula |
C20H20O7
|
---|---|
Molecular Weight |
372.3686
|
CAS # |
2306-27-6
|
SMILES |
O1C(=C([H])C(C2=C(C(=C(C([H])=C12)OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])=O)C1C([H])=C([H])C(=C(C=1[H])OC([H])([H])[H])OC([H])([H])[H]
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~50 mg/mL (~134.28 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.36 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6855 mL | 13.4275 mL | 26.8550 mL | |
5 mM | 0.5371 mL | 2.6855 mL | 5.3710 mL | |
10 mM | 0.2686 mL | 1.3428 mL | 2.6855 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.